From Diagnosis to Lifestyle The Impact of Sports on MODY Diabetes Management
DOI:
https://doi.org/10.12775/QS.2024.17.52985Keywords
Diabetes, MODY, sulfonylurea derivatives, physical activity in diabetesAbstract
Introduction and objectives: Diabetes is a group of diseases that is currently estimated to affect approximately 537 million adults worldwide. Diabetes can develop due to many factors, including autoimmunity, genetics and insulin resistance. The presented article will discuss the type of monogenic diabetes - maturity onset diabetes in young. This is a relatively rare form of diabetes, affecting no more than 5% of patients with the disease, but it is important to correctly differentiate it and implement appropriate therapy to prevent the development of complications. In addition, the article discusses a group of antidiabetic drugs - sulfonylurea derivatives, which are widely used in diabetic patients.
Review and methods: Review and summary of studies and scientific articles avaliable in open-source format on Google Scholar and PubMed.
Abbreviated description of the state of knowledge: The diagnosis of MODY diabetes is more extensive than that of the most common types in the population - type 1 and type 2 diabetes.
Individual forms of MODY diabetes differ in the location of the mutation in the genome. As a result, the MODY group is heterogeneous, with individuals differing in the severity of symptoms, the treatment used and the presence of developmental abnormalities affecting various organ systems.
Sulfonylurea derivatives are a group of drugs that have been used to treat diabetes since the mid-20th century. Their mechanism of action is to stimulate insulin secretion, so it is necessary to preserve at least some of the function of the beta cells in the pancreatic islets when using them.
Summary: A collection of information on MODY diabetes is presented based on a review of research and scientific articles. In addition, the section on sulfonylureas provides an overview of first- and second-generation drugs and compares them. The article also highlights the important role of physical activity in managing diabetes and preventing complications.
References
https://www.who.int/news-room/fact-sheets/detail/diabetes
Sanyoura M, Philipson LH, Naylor R. Monogenic diabetes in children and adolescents: recognition and treatment options. Curr Diab Rep. 2018;18(8):58.
DOI: 10.1007/s11892-018-1024-2
Fajans SS, Bell GI. MODY: history, genetics, pathophysiology, and clinical decision making. Diabetes Care. 2011;34(8):1878–84.
DOI: 10.2337/dc11-0035
Hoffman LS, Jialal I. Diabetes, maturity onset in the young (MODY). In: StatPearls. Treasure Island: StatPearls Publishing; 2019.
Firdous P, Nissar K, Ali S, Ganai BA, Shabir U, Hassan T, Masoodi SR. Genetic testing of maturity-onset diabetes of the young current status and future perspectives. Front Endocrinol (Lausanne). 2018;9:253.
DOI: 10.3389/fendo.2018.00253
Peixoto-Barbosa R, Reis AF, Giuffrida FMA. Update on clinical screening of maturity-onset diabetes of the young (MODY). Diabetol Metab Syndr. 2020;8(12):50.
DOI: 10.1186/s13098-020-00557-9
Stanik J, Dusatkova P, Cinek O, Valentinova L, Huckova M, Skopkova M, et al. De novo mutations of GCK, HNF1A and HNF4A may be more frequent in MODY than previously assumed. Diabetologia. 2014;57(3):480–4.
DOI: 10.1007/s00125-013-3119-2
Urbanová J, Brunerová L, Brož J. Hidden MODY-looking for a needle in a haystack. Front Endocrinol (Lausanne). 2018;9:355.
DOI: 10.3389/fendo.2018.00355
Kleinberger JW, Pollin TI. Undiagnosed MODY: time for action. Curr Diab Rep. 2015;15(12):110.
DOI: 10.1007/s11892-015-0681-7
Irgens HU, Molnes J, Johansson BB, Ringdal M, Skrivarhaug T, Undlien DE, et al. Prevalence of monogenic diabetes in the population-based Norwegian childhood diabetes registry. Diabetologia. 2013;56(7):1512–9.
DOI: 10.1007/s00125-013-2916-y
T. J. McDonald, K. Colclough, R. Brown, B. Shields, M. Shepherd, P. Bingley, A. Williams, A. T. Hattersley, Sian Ellard https://doi.org/10.1111/j.1464-5491.2011.03287.x
Hattersley AT, Greeley SAW, Polak M, et al. ISPAD Clinical Practice Consensus Guidelines 2018: the diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes. 2018;19(Suppl 27):47–63.
DOI: 10.1111/pedi.13426
Pearson ER, Pruhova S, Tack CJ, et al. Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4alpha mutations in a large European collection. Diabetologia. 2005;48(5):878–85
DOI: 10.1007/s00125-005-1738-y
Delvecchio M, Salzano G, Bonura C, et al. Can HbA1c combined with fasting plasma glucose help to assess priority for GCK–MODY vs HNF1A-MODY genetic testing? Acta Diabetol. 2018;55(9):981–3.
DOI: 10.1007/s00592-018-1179-y
Stride A, Vaxillaire M, Tuomi T, et al. The genetic abnormality in the beta cell determines the response to an oral glucose load. Diabetologia. 2014;45(3):427–35.
Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet. 2003;362(9392):1275–81
DOI: 10.1016/S0140-6736(03)14571-0
Ahlgren U, Jonsson J, Jonsson L, Simu K, Edlund H.Beta-cell-specific inactivation of the mouse Ipf1/ Pdx1 gene results in loss of the betacell phenotype and maturity onset diabetes. Genes Dev. 1998;12: 1763–8
DOI: 10.1101/gad.12.12.1763
Dubois-Laforgue D, Cornu E, Saint-Martin C, et al. Diabetes, associated clinical spectrum, long-term prognosis, and genotype/phenotype correlations in 201 adult patients with hepatocyte nuclear factor 1B (HNF1B) molecular defects. Diabetes Care. 2017;40(11):1436–43
DOI: 10.2337/dc16-2462
Kapoor RR, Flanagan SE, James CT, et al. Hyperinsulinaemic hypoglycaemia and diabetes mellitus due to dominant ABCC8/KCNJ11 mutations. Diabetologia. 2011;54:2575–83.
DOI: 10.1007/s00125-011-2207-4
Bowman P, Sulen A˚ , Barbetti F, et al. Effectiveness and safety of long-term treatment with sulfony lureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study. Lancet Diabetes Endocrinol. 2018;6(8):637–46.
DOI: 10.1016/S2213-8587(18)30106-2
Bonnefond A, Philippe J, Durand E, et al. Whole exome sequencing and high throughput genotyping identified KCNJ11 as the thirteenth MODY gene. PLoS One. 2012;7(6):e37423.
DOI: 10.1371/journal.pone.0037423
Prudente S, Jungtrakoon P, Marucci A, et al. Loss-of-function mutations in APPL1 in familial diabetes mellitus. Am J Hum Genet. 2015;97:177–85.
DOI: 10.1016/j.ajhg.2015.05.011
Neve B, Fernandez-Zapico ME, Ashkenazi-Katalan V, et al. Role of transcription factor KLF11 and its diabetes-associated gene variants in pancreatic beta cell function. Proc Natl Acad Sci USA. 2005;102(13):4807–12
DOI: 10.1073/pnas.0409177102
Raeder H, Johansson S, Holm PI, et al. Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction. Nat Genet. 2006;38:54–62
DOI: 10.1038/ng1708
Sujjitjoon J, Kooptiwut S, Chongjaroen N, Tangjit-tipokin W, Plengvidhya N, Yenchitsomanus PT. Aberrant mRNA splicing of paired box 4 (PAX4) IVS7-1G[A mutation causing maturity-onset dia-betes of the young, type 9. Acta Diabetol. 2016;53(2):205–16.
DOI: 10.1007/s00592-015-0760-x
Molven A, Ringdal M, Nordbø AM, et al. Mutations in the insulin gene can cause MODY and autoan-tibody-negative type 1 diabetes. Diabetes. 2008;57(4):1131–5.
DOI: 10.2337/db07-1467
Borowiec M, Liew CW, Thompson R, et al. Mutations at the BLK locus linked to maturity onset diabetes of the young and beta-cell dysfunction. Proc Natl Acad Sci USA. 2009;106(34):14460–5
DOI: 10.1073/pnas.0906474106
Janbon M, Chaptal J, Vedel A, Schaap J. Accidents
hypoglycémiques graves par un sulfamidothiodiazol (le VK57 ou 2254 RP). Montpellier Med 1942, 441: 21-22.
Burke MA, Mutharasan RK, Ardehali H. The sulfonylurea receptor, an atypical ATP-binding cassette protein, and its regulation of the KATP channel. Circ Res 2008, 102(2):164-176
DOI: 10.1161/CIRCRESAHA.107.165324
https://journals.viamedica.pl/clinical_diabetology/article/download/18134/14288
Schernthaner G., Grimdali A., Di Mario V. i wsp. GUIDE Study:double blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur. J. Clin. Invest. 2004;34: 535–542.
DOI: 10.1111/j.1365-2362.2004.01381.x
https://diabetyk.pl/leki/pochodne-sulfonylomocznika/
https://journals.viamedica.pl/clinical_diabetology/article/download/8915/7581
Shugart C, Jackson J, Fields KB. Diabetes in sports. Sports Health. 2010;2(1):29-38. DOI:10.1177/1941738109347974
“Interna Szczeklika - mały podręcznik 2018/2019” P. Gajewski, wydawnictwo Medycyna Praktyczna, Kraków 2018, wydanie 10
https://iris.who.int/bitstream/handle/10665/341120/WHO-EURO-2021-1204-40953-58211-pol.pdf?sequence=1
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Kamil Gała, Konrad Pilarski, Adam Kucharski, Rafał Makuch, Alicja Chrościcka , Andrzej Czajka, Paweł Lenard, Sara Michalska, Martyna Dewicka, Alicja Maria Wawrzyniak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 175
Number of citations: 0
